Introduction {#Sec1}
============

An estimated 2.1 million people were infected with HIV in 2015 (Unaids [@CR53]). Despite increasing numbers of people on antiretroviral treatment (ART), there is still a need to scale up HIV prevention in order to counter the global epidemic on a population level. Existing prevention modalities such as condoms, medical male circumcision, treatment as prevention, and oral pre-exposure prophylaxis (PrEP) face limitations such as negotiability, stigma, access, adherence, retention, and efficacy (Pettifor et al. [@CR38]; Celum et al. [@CR9]). A breakthrough in HIV prevention such as a highly effective vaccine is urgently needed. The Pox-Protein Public-Private Partnership (P5) is working to build on the findings of the RV144 trial (Russell and Marovich [@CR43]) with a currently ongoing Phase 2b/3 trial (HVTN 702) in South Africa (ClinicalTrails [@CR10]). The vaccine tested in the Thailand-based RV 144 trial consisted of one prime dose (canarypox vector with *gag, pol* and *env* HIV genes) followed by two prime--boost doses (adding the viral protein *gp120*). Modified intent-to-treat analysis showed marginal efficacy of $\documentclass[12pt]{minimal}
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                \begin{document}$$\sim 30\%$$\end{document}$ protection against heterosexual HIV acquisition. HTVN 702 builds on RV 144 by utilizing the same vector with HIV genes specific to the clade predominantly circulating in South Africa, a different adjuvant and an extended regimen of five doses. With its complex immunization schedule and anticipated waning of immunity, the regimen is likely to provide only partial efficacy over limited time. Such vaccine could be seen as a first-generation product that must still be improved upon in order to fundamentally transform the HIV epidemic. Mathematical models (Medlock et al. [@CR33]; Hontelez et al. [@CR25]; Smith et al. [@CR50]; Andersson and Stover [@CR2]; Harmon et al. [@CR24]; Moodley et al. [@CR34], [@CR35]; Hankins et al. [@CR22]; Phillips et al. [@CR39]; Adamson et al. [@CR1]; de Montigny et al. [@CR13]) suggest that the first-generation vaccine would be useful and cost-effective to roll out, but that its overall impact will be modest. Here, we explore what factors contribute collectively to limiting the impact of such a vaccine.

Methods {#Sec2}
=======

Motivated by the HIV vaccine trial HVTN 702 currently ongoing in South Africa, we developed an agent-based model of the HIV epidemic in the South African population to forecast HIV infections over a 20-year time horizon, from year 2027 to 2047. The choice of this time horizon was based on the originally planned primary completion date of the vaccine trial in 2021 (ClinicalTrails [@CR10]) and delays in its start. Thus, the year 2027 was assumed as plausible earliest possible rollout of mass vaccination. As compared to a reference case with no HIV vaccine, we evaluate implementation of strategies for initiation of HIV vaccination in a population aged between 18 and 34.

Model setup and calibration {#Sec3}
---------------------------

We modified EMOD-HIV v2.5, an age-stratified and individual-based network model of HIV of South Africa, to incorporate HIV vaccination according to pox-protein HIV vaccine regimens (such as the regimen currently being tested in HVTN 702). Because EMOD is an individual-based model, interventions such as a time-varying course of vaccine efficacy can be applied to each individual according to his or her own timing of vaccination and adherence to the booster series. This renders the model well suited for a nuanced analysis of the anticipated time-dependent efficacy of the pox-protein HIV vaccine regimen.

The parameters, model input values, sources, projections, and sensitivities of the epidemic projection without vaccine, used as the reference group for comparison, have been described previously (Bershteyn et al. [@CR5], [@CR6]; Klein et al. [@CR30]; Selinger et al. [@CR46]). A detailed model description, default parameters, user tutorials, model installer, and source code are available for download at <http://idmod.org/software>. EMOD-HIV is an individual-based model that simulates transmission of HIV using an explicitly defined network of heterosexual relationships that are formed and dissolved according to age- and risk-dependent preference patterns (Klein [@CR29]). The synthetic population was initiated in 1960, and population recruitment and mortality were assumed to be proportional following age- and gender-stratified fertility and mortality tables and projections from the 2012 UN World Population Prospects (UnitedNations [@CR55]). Since the population size of South Africa exceeds the computational limit of simulated agents, we assumed that one simulated agent corresponds to 300 real-world individuals. The model was calibrated to match retrospective estimates of age- and gender-stratified, national-level prevalence, incidence, ART coverage and all-cause mortality from nationally representative HIV surveys in South Africa (Shisana et al. [@CR48], [@CR49]; Eaton et al. [@CR20]; Rehle et al. [@CR40]; Shisana and Simbayi [@CR47]) and demographic data (Statistics South Africa [@CR52]) (see Figure 1 in Supplementary Materials for an overlay between model calibration outputs and source data). We also refer to a comparative calibration study comprising ten models (including EMOD) of HIV transmission in South Africa (see supplementary material in Eaton et al. [@CR20]). For the purpose of this modeling study, we emphasized calibration of model parameters concerning risk assortativity during partnership formation, duration, and concurrency of partnerships as well as condom usage. For each simulated vaccine scenario, we used the 50 most likely parameter sets obtained from the gradient-descent-based calibration process (see Table 1 in Supplementary Material). The age patterns of sexual mixing were configured to match those observed in the rural, HIV-hyperendemic province of KwaZulu-Natal, South Africa (Ott et al. [@CR37]). Recently, a validation study showed that self-reported partner ages in this setting are relatively accurate, with 72% of self-reported estimates falling within 2 years of the partners\' actual date of birth (Harling et al. [@CR23]). In addition, a recent field study on age-mixing patterns in Cape Town came to similar conclusions concerning the age gap between men and women (Beauclair et al. [@CR4]), suggesting that the age-mixing data used in our model is not specific to KwaZulu-Natal but applies more generally to South Africa. Further, the transmission patterns observed in EMOD (Bershteyn et al. [@CR6]) are consistent with those revealed in a recent phylogenetic analysis of the age/gender patterns of HIV transmission in this setting (de Oliveira et al. [@CR14]).

Transmission rates within relationships depend on HIV disease stage, male circumcision, condom usage, coinfections. Viral suppression achieved through antiretroviral therapy (Attia et al. [@CR3]; Marconi et al. [@CR32]) is assumed to reduce transmission by 92%---an estimate based on observational data of serodiscordant couples in which outside partnerships could have contributed to HIV acquisition (Donnell et al. [@CR17]).

HIV treatment and prevention {#Sec4}
----------------------------

We configured the EMOD healthcare system module to follow trends in antiretroviral therapy (ART) expansion in South Africa. Treatment begins with voluntary counseling and testing (VCT), antenatal and infant testing, symptom-driven testing, and low level of couples testing. The model includes loss to follow-up between diagnosis and staging, between staging and linkage to ART or pre-ART care, and during ART or pre-ART care (Mugglin et al. [@CR36]). Projections of South Africa treatment expansion in the no-vaccine reference group are calibrated to reflect a gradual decline of HIV incidence without elimination, so that HIV remains endemic through 2050 (Eaton et al. [@CR19]). All scenarios included medical male circumcision (Connolly et al. [@CR12]) at 22% coverage and conferring 60% reduction in acquisition risk with lifetime durability. Condom usage was dependent on four relationship types (transitory, informal, marital, and commercial), with per act usage probability ramping up to median values of 62%, 39%, 26%, and 85% by 2027 across parameter draws. To allow for maximum hypothetical impact of a vaccine, we assume proportion of HIV-positive adults diagnosed of about 85% and future ART coverage of about 60% \[consistent with the current guidelines assumed in the HIV/TB Investment Case Report for South Africa (South African National AIDS Council [@CR51]), see also (Johnson et al. [@CR27])\] and no use of oral PrEP. Variations on these assumptions, explored elsewhere (Selinger et al. [@CR45], [@CR46]), only further diminish the impact of the vaccine.

HIV vaccine efficacy {#Sec5}
--------------------

We incorporated a parametric model of time-dependent vaccine efficacy that was hypothesized for the pox-protein regimen based on results from RV144. We included the time series of efficacy associated with each of the originally planned five doses administered during the study and possible booster doses (described in detail below) beyond the 24-month duration of the first stage of the study. Specifically, the pox-protein dosing schedule that was modeled consisted of a series of five immunizations over 12 months. ALVAC-HIV-C was administered at months 0 and 1, followed by ALVAC-HIV-C+gp120 at months 3, 6, and 12. The protocol was later revised to include a boost at month 18, but this was not considered at the time of this modeling effort. Time-dependent vaccine efficacy was interpreted as a per exposure reduction in the probability of acquisition parameterized by an impulse and exponential decay model (Selinger et al. [@CR46]).$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\begin{aligned}&\text {TimeDependentVaccineEfficacy}(t)\\&\quad :=\sum _{i\in \text {Schedule}, i\le t} (a_i+b_i)\hbox{e}^{-\omega (t-i+d)} \end{aligned}$$\end{document}$$where $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$a_i$$\end{document}$ is the efficacy increase of immunization with ALVAC-HIV-C, $\documentclass[12pt]{minimal}
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                \begin{document}$$\omega$$\end{document}$ is the efficacy decay rate per month, and *d* is the delay between immunization and initiation of protective effect in months.

Assuming uniformly distributed exposure over a given time span in the trial, we calculated the cumulative vaccine efficacy (corresponding to the efficacy estimate from the trial) as the area under the curve of the instantaneous vaccine efficacy rescaled by the length of the time span.$$\documentclass[12pt]{minimal}
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Booster schedule and efficacy {#Sec6}
-----------------------------

For the purpose of model projections beyond the primary trial endpoint, we also implemented up to four two-yearly boosters starting at month 36 with fixed return rates of 100, 80, or 50% per booster to cover a total of 10 years of vaccine efficacy. We assumed booster efficacy to follow the same parameterization as ALVAC-HIV-C + gp120 doses from the primary immunization series during the first 12 months. Booster eligibility depended on having received the primary immunization series or the booster previously. Missing a booster resulted in loss of eligibility for subsequent boosters, which may or may not prove to be the case when the vaccine is implemented. Individuals who tested HIV positive were not eligible for future boosters. We assumed that four booster doses after the primary first-year series were necessary to confer one decade of protection. Booster eligibility was limited by the target age range of catch-up vaccination (see below).

Nested hierarchy of vaccination {#Sec7}
-------------------------------

Because of the nested sequence of steps that are required for a partially effective vaccine to confer benefit, we conceptualized the steps as a cascade of prevention (Garnett et al. [@CR21]), analogous to the "cascade of care" in which an individual must be diagnosed, initiated on treatment, and achieving viral suppression in order to maximally benefit from HIV care and treatment (Johnson et al. [@CR27]). We simulated a series of vaccination scenarios, sequentially incorporating different limitations of the vaccine and its rollout (see Table [1](#Tab1){ref-type="table"}). For each limitation, we quantified the decline in population-level impact, as measured by the percent reduction in cumulative new infections relative to a base case scenario without vaccine between 2027 and 2047 for individuals aged 15--49. Since we did assume neither scale-up of ART coverage nor use of oral pre-exposure prophylaxis in the time period under investigation, percent reduction in new infections represents an upper bound relative to the maximum number of new infections prevented; i.e., more optimistic assumptions on ART scale-up would result in less infections prevented.

In all simulation scenarios, we assumed an initial catch-up vaccination campaign starting in 2027, where all men and women aged between 18 and 34 would be vaccinated, followed by vaccination of all 18-year-olds in subsequent years until 2047. The scenarios differed by the time it would take to scale up catch-up vaccination, and also by coverage, durability, and efficacy of the vaccine. First, we considered an idealized vaccine, providing complete protection (indefinite, 100% efficacy) without waning and available for use in 2027, even though we recognize the impracticality of such a scenario. Second, we simulated a more gradual vaccination, assuming a 5-year linear scale-up of catch-up vaccination starting in 2027 before reaching full coverage by 2032, from which on 18-year-olds are vaccinated in subsequent years until 2047. Third, we considered a vaccine with limited duration of complete protection, assuming 10 years of full efficacy (100%), after which vaccine recipients were no longer protected. Next, we simulated a vaccine with partial efficacy that varied over 10-year protection period, averaging 50% over the first 2 years (including the first year of intensive vaccination) and falling to 15--30% over the next 8 years depending on booster frequency. Finally, we considered a wide range of hypothetical coverage levels of 60, 30, and 10% at various return rates for booster vaccination. We chose a population aged 15--49 as reference group to cover the sexually active population and vaccination age between 18 and 34 to target the core of the population at risk. The age range used for vaccination in our model is the same as in the currently ongoing vaccine trial HVTN 702. Adolescent vaccination would require further licensure procedures and potentially delay vaccination scale-up and was therefore excluded. The impact of age- and gender-dependent targeting for this vaccine regimen was explored elsewhere (Selinger et al. [@CR46]).Table 1Nested hierarchy of vaccination scenarios simulated for South Africa over the years 2027 through 2047ScenarioCoverage (%)Scale-up (years)Efficacy (%)Durability (years)WaningReturn rate for booster (%)1100010020NoNA2100510020NoNA3100510010NoNA410055010Yes10056055010Yes10063055010Yes10071055010Yes100810055010Yes8096055010Yes80103055010Yes80111055010Yes801210055010Yes50136055010Yes50143055010Yes50151055010Yes50

Results {#Sec8}
=======

Modeling results (see Fig. [1](#Fig1){ref-type="fig"}) suggest that an ideal vaccine available in 2027 and covering all 18--34-year-olds could prevent 89% of all infections occurring in the South African population aged 15--49 over the 2027--2047 interval. A more realistic 5-year scale-up to reach full coverage entails a modest drop in impact to 79%, while limiting protection durability to 10 years results in a further drop to 66% infections averted. The second large reduction in intervention impact (from 66% to 20%) is due to assumptions of partial and waning efficacy. In total, factors related to vaccine durability, scale-up, and efficacy result in a difference of 69% in vaccination effectiveness. Decreasing coverage from 100 to 60% will further attenuate the epidemic impact to just above 14% while problems with retention to the series of boosters will prevent as few as 11% of cumulative infections. In our most pessimistic scenario, assuming 10% coverage and 50% booster return rate, the epidemic impact drops down to 3% of infections averted.

Another way to visualize the implications of the simulated vaccination scenarios is considering the epidemic curves, i.e., average annual number of new infections (see Figure 2 in Supplementary Materials). Starting out with an estimated 362,000 new infections in 2017, the first two scenarios with vaccination in 2027 at hypothetical 100% efficacy would lead to less than 1000 new infections in 2047. Limited durability of the same vaccine increases new annual infections to 96,000 and efficacy assumptions of 50% with waning results in 260,000 new infections in 2047. Achieving high return rates for booster vaccination produces little change in the epidemic curve.Fig. 1Percent reduction in cumulative new infections in a nested hierarchy of HIV vaccination scenarios. The percent values refer to the cumulative number of infections prevented by vaccination in South Africa between 2027 and 2047 in populations aged 15--49, divided by the cumulative number of infections in non-vaccine reference simulations for the same time period and age range

Discussion {#Sec9}
==========

This modeling analysis of a nested hierarchy of vaccination clearly highlights three dominant reasons for the limited population-level impact of a partially effective HIV vaccine, namely the time required to scale up mass vaccination, limited durability and waning of efficacy. Each of these obstacles poses particular challenges for public health implementation. First, fast and high uptake of an HIV vaccine in South Africa will be difficult to achieve in an adult catch-up population, compared to the success of the school-based two-dose Human Papillomavirus (HPV) Vaccination Program (Delany-Moretlwe et al. [@CR15]). In addition to logistic challenges for vaccine manufacturers and healthcare systems, acceptance for a newly introduced vaccine within a short period of time may prove crucial. Indeed, research in social psychology stresses that HIV testing, HIV stigma, mistrust of the healthcare system, and concerns about sexual disinhibition may be barriers to vaccine uptake in young adults, with noticeable differences between men and women (Sayles et al. [@CR44]; Rubincam et al. [@CR42]). Second, limited durability raises the questions whether revaccination with a complex regimen 10 years after the initial vaccination can be implemented at high coverage, given the challenges of achieving high vaccination rates in adults (CDC [@CR8]). Finally, partial efficacy and waning remain the strongest factors limiting impact at the population level.

We simulated 50% efficacy at month 24 as an illustration, but we hope that efficacy in HVTN 702 will be higher due to the modified regimen compared to RV144. From a public health perspective, the rollout of a partially effective, quickly waning vaccine must be considered with caution and as an addition to existing HIV prevention measures, as it is only a first step toward vaccine development with improved immunogenicity.

The present modeling study bears several limitations. The uncertainty in the number of new infections when reaching the prospective start of mass vaccination in 2027 is a major one. Although recently published numbers of 270,000 (95% CI 240,000--300,000) new infections in South Africa in 2017 (Unaids [@CR54]) are in line with our simulation results of 362,000 new infections (bearing in mind the more pessimistic assumptions on ART scale-up in our model), it remains difficult to anticipate dynamics of the HIV epidemic over a longer timescale. Another limitation stems from the fact that in South Africa, the HIV epidemic is highly heterogeneous between provinces, mostly differing in prevalence of male circumcision and non-marital relationships (Johnson et al. [@CR26]). In this context, national-level models (such as the present study) must be utilized with caution; e.g., it has been shown that spatial heterogeneity and associated migration strongly influence HIV transmission  (Bershteyn et al. [@CR7]; Dobra et al. [@CR16]; Coffee et al. [@CR11]; Voeten et al. [@CR56]) and therefore vaccination implementation. Considering constrained vaccine coverage regarding heterogeneously distributed geospatial and behavioral risk would raise ethical questions of how to devise vaccine rollout in an optimal way  (Keeling and Shattock [@CR28]). At last, we would like to mention the likely impact of risk compensation (Eaton and Kalichman [@CR18]; MacPhail et al. [@CR31]). Increases in risky behavior by vaccine recipients and their partners such as reductions in condom use and an increase in multiple partners potentially impair population-level vaccine impact, especially for a partially effective vaccine.

Our analysis suggests that optimizing the efficacy of a broadly used vaccine should be a continuous process because of its critical contribution to the vaccination impact. Maximizing coverage has been rightly in the focus of all effectiveness analyses since it is likely to pose a challenge for a vaccine candidate with such a complex and lengthy dosing schedule. However, its ability to improve vaccination impact is already limited by the speed of vaccine rollout and imperfect efficacy. Timely scale-up of manufacturing capacities, improved immunogenicity, and reassessing risk--benefit considerations for target populations with high-risk profile during the licensure process could help to overcome the major obstacles to population-level impact identified in this analysis.

Model-based estimates of the impact of pox-protein-like vaccines are often met with disappointment. Several modeling studies have explicitly considered waning efficacy in a South African context and concluded that only frequent revaccination at high coverage would yield proportions of infections prevented appreciably high at about 15% (Andersson and Stover [@CR2]; Hontelez et al. [@CR25]). Our modeling study contributes to the existing body of evidence in several ways. First, it is based on the currently ongoing HTVN 702 trial (more realistic start of vaccine rollout, a more detailed immunization schedule). Second, our model is unique in that it is an age-structured agent-based network model, such that secondary benefits of vaccination within sexual contact networks can also be factored in. Third, it explores systematically possible shortcomings of the vaccine.

This analysis aims to clarify why the absolute impact of a partially effective multi-dose vaccine with limited durability is likely to be modest. Though worthwhile to develop and make available, such a vaccine is unlikely to reverse the course of the HIV epidemic. Rather, a first-generation partially effective vaccine would primarily serve as an intermediate milestone, furnishing correlates of immunity and platforms that could serve to accelerate future development of a highly effective, durable, and scalable next-generation vaccine capable of reversing the HIV epidemic.
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